Mode
Text Size
Log in / Sign up
Phase 2 N=25 Randomized Double-blind Treatment

Interleaved TMS-fMRI for Hippocampal Stimulation: Modeling Dose-Response Relationship in Amnestic Mild Cognitive Impairment

Mild Cognitive Impairment

Enrolled (actual)
25
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcome: Primary: Correction Rate in Memory Association Recall — .106; .031 units on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Transcranial Magnetic Stimulation (Device); Transcranial Magnetic Stimulation (Sham) (Device)
Age
Adult, Older Adult · 50+ yrs
Sex
All
Sponsor
University of Arizona
Primary completion
Mar 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Correction Rate in Memory Association Recall
.106; .031

Summary

Emerging evidence indicates that dysfunction of hippocampal synaptic plasticity, which precedes neuronal degeneration during the progression of Alzheimer's disease (AD), underlies the hallmark cognitive impairment. Although there are currently no effective disease modifying treatments for AD, recent preclinical studies in animal models of AD have suggested that repetitive transcranial magnetic stimulation (rTMS) promotes hippocampal synaptic plasticity and, ultimately, improves learning and memory abilities. Interleaved TBS-MRI is a paradigm, which allows the investigators to study human brain functionality with real-time MRI, to better understand modulations of brain activity in response to the non-invasive brain stimulation, TBS. The interleaved TBSfMRI paradigm can more accurately estimated the immediate brain activity compared to the offline TBS-MRI studies in which TBS is applied outside the MRI. With this interleaved TBS-MRI approach, the investigators will be able to measure immediate changes in targeted brain activity, such as hippocampus activation, following each TBS session. This approach has created the unprecedented potential enabling the investigators to model the dose-dependent effects of TBS more accurately on brain function.

Eligibility Criteria

Inclusion Criteria

  • Age 50-80 years
  • MCI clinical criteria: (a) self- or informant-reported cognitive complaint; (b) preserved independence in functional abilities; and (c) absence of dementia.
  • Objective cognitive impairment supported by the following measures of general cognitive function: (a) Mini-Mental State Exam (MMSE) 24-27 (inclusive); (b) Montreal Cognitive Assessment (MoCA) 18-26 (inclusive); or (c) Clinical Dementia Rating Scale score of 0.5.
  • Right handed
  • English speaking
  • Able to attend daily intervention (Monday-Friday) for 4 days
  • Not enrolled in another interventional study within 6 months prior to beginning this study

Exclusion Criteria

  • Contraindications to transcranial magnetic stimulation (TMS) or magnetic resonance imaging (MRI)
  • Other neurological disorders (e.g. stroke, head injuries, or multiple sclerosis)
  • Untreated depression
  • Current cancer treatment or other medical problems that might independently affect cognitive function
  • Clinical Dementia Rating Scale score more than 1.0
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05515952). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search